Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 6/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 6/20 | 0.60 |
| ▸ | CNR1 | P21554 | 7/20 | 0.45 |
| ▸ | CNR2 | P34972 | 6/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8792553 | 0.89 | SRD5A1 (0.72) | SRD5A1SRD5A2CNR1CNR2CREBBP | |
| SCHEMBL9335630 | 0.86 | SRD5A1 (0.58) | SRD5A1SRD5A2CNR1CNR2CREBBP | |
| SCHEMBL3405579 | 0.85 | SRD5A1 (0.69) | SRD5A1SRD5A2CNR1CNR2CREBBP | |
| Hydrochloric Acid SCHEMBL8793984 | 0.84 | SRD5A1 (0.68) | SRD5A1SRD5A2CNR1CNR2CREBBP | |
| SCHEMBL8793528 | 0.82 | SRD5A1 (0.65) | SRD5A1SRD5A2CNR1CNR2CREBBP | |
| SCHEMBL5701972 | 0.80 | SRD5A1 (0.74) | SRD5A1SRD5A2CNR1CNR2CREBBP | |
| SCHEMBL8792796 | 0.79 | SRD5A1 (0.80) | SRD5A1SRD5A2CNR1CNR2CREBBP | |
| SCHEMBL8792776 | 0.79 | SRD5A1 (0.61) | SRD5A1SRD5A2CNR1CNR2CREBBP | |
| SCHEMBL9604317 | 0.78 | SRD5A1 (0.59) | SRD5A1SRD5A2CNR1CNR2CREBBP | |
| SCHEMBL27314275 | 0.78 | SRD5A1 (0.74) | SRD5A1SRD5A2CNR1CNR2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1302460-B1 | Indolecarboxylic compounds and their use as pharmaceutical compounds | OREAL (FR) | 2006-08-02 | — | — | EP | disclosed |
| US-6596753-B2 | Effective amount of at least one compound of the indolecarboxylic family, this compound or these compositions being intended to treat disorders associated with overactivity of 5 alpha -reductase. These compositions treat androgen | SOCIETE L'OREAL S.A. (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | BERNARD BRUNO (FR) | 2003-03-13 | — | — | US | disclosed |
| EP-0964852-B1 | INDOLECARBOXYLIC COMPOUNDS AND THEIR USE AS PHARMACEUTICAL COMPOUNDS | OREAL (FR) | 2003-03-12 | — | — | EP | disclosed |
| US-6448285-B1 | DISORDERS ASSOCIATED WITH OVERACTIVITY OF 5 ALPHA REDUCTASE; ANDROGEN DEPENDENT DISORDERS SUCH AS SEBORRHOEA, ACNE, HIRSUTISM AND/OR ANDROGENIC ALOPECIA | SOCIETE L'OREAL S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | CYP17A1, SRD5A1, SRD5A2 | SRD5A1 2/4885SRD5A2 3/4885CNR1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.